Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | DHODH | Q02127 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5775864 | 0.90 | SMN1; SMN2 (0.47) | MAPTSMN1; SMN2TP53DHODHALDH1A1 | |
| SCHEMBL5771355 | 0.89 | MAPT (0.39) | MAPTSMN1; SMN2TP53DHODHLMNA | |
| SCHEMBL5777446 | 0.87 | MEN1 (0.41) | MAPTSMN1; SMN2TP53DHODHALDH1A1 | |
| SCHEMBL5777020 | 0.87 | MAPT (0.42) | MAPTSMN1; SMN2TP53ALDH1A1LMNA | |
| SCHEMBL5771724 | 0.87 | MAPT (0.41) | MAPTSMN1; SMN2TP53DHODHALDH1A1 | |
| SCHEMBL5771411 | 0.86 | TP53 (0.54) | MAPTSMN1; SMN2TP53DHODHLMNA | |
| SCHEMBL5772996 | 0.85 | MAPT (0.36) | MAPTSMN1; SMN2TP53DHODHALDH1A1 | |
| SCHEMBL5773239 | 0.84 | MAPT (0.37) | MAPTSMN1; SMN2TP53DHODHLMNA | |
| SCHEMBL5776170 | 0.84 | PTPN1 (0.36) | MAPTSMN1; SMN2TP53DHODHALDH1A1 | |
| SCHEMBL5776209 | 0.84 | MAPT (0.35) | MAPTSMN1; SMN2TP53DHODHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | MAPT 4701/4885SMN1; SMN2 3383/4885TP53 4371/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | MAPT 4763/4885SMN1; SMN2 2449/4885TP53 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.